NCT03473977 - Benralizumab for Eosinophilic Gastritis (BEGS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

June 22, 2020

Study Completion Date

January 12, 2022

Conditions

Eosinophilic Gastritis or Gastroenteritis

Interventions

BIOLOGICAL

Benralizumab

Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.

BIOLOGICAL

Placebo

Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.

Trial Locations (1)

Cincinnati Children's Hospital Medical Center, Cincinnati